Regulation of the hepatic removal of chylomicron remnants and beta-very low density lipoproteins in the rat.
The contribution of the low density lipoprotein (LDL) receptor to the removal of chylomicron remnants was determined in vitro and in vivo by using interventions that up- or down-regulate the LDL receptor but not the LDL receptor-related protein (LRP). In vitro, chylomicron remnants and beta-very low density lipoprotein (VLDL) bind to the LDL receptor on endosomal membranes; their binding can be competed by LDL and beta-VLDL and the binding capacity is greatly augmented in membranes from estradiol-treated rats. Likewise, estradiol treatment almost doubled the removal of chylomicron remnants during a single pass through perfused rat livers. However, in vivo the removal of chylomicron remnants and beta-VLDL was very rapid even in untreated rats so that the effect of the stimulation by estradiol was barely detectable when trace amounts of lipoproteins were injected. Yet, when saturating doses of either lipoprotein were injected, the effect of estradiol treatment on the removal of chylomicron remnants and beta-VLDL was readily disclosed. In rats fed a diet containing lard, cholesterol, and bile acids, removal of chylomicron remnants or beta-VLDL was significantly retarded. Likewise, perfused livers from diet-fed rats removed only a mean of 16% of chylomicron remnants during a single passage as compared to 29% in livers from control animals. Also, when large doses of beta-VLDL had been infused into rats for 4 h, in subsequent perfusions of the livers the removal of chylomicron remnants was decreased to 11%. From these results it is concluded that the LDL receptor mediates the hepatic removal of a major fraction of chylomicron remnants and beta-VLDL.
Jäckle
S
S
Medizinsche Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, Hamburg, Germany.
Rinninger
F
F
Greeve
J
J
Greten
H
H
Windler
E
E
D000818:Animals; D001667:Binding, Competitive; D002914:Chylomicrons / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D004041:Dietary Fats / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects; D004958:Estradiol / Q000494:pharmacology; D006801:Humans; D008079:Lipoproteins, VLDL / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D008099:Liver / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D008297:Male; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D011973:Receptors, LDL / Q000187:drug effects / Q000502:physiology*; D015854:Up-Regulation / Q000187:drug effects
D002914:Chylomicrons; D004041:Dietary Fats; D008079:Lipoproteins, VLDL; D011973:Receptors, LDL; D004958:Estradiol